Back to Search
Start Over
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
- Source :
-
Cancer Chemotherapy & Pharmacology . Jul2020, Vol. 86 Issue 1, p109-115. 7p. - Publication Year :
- 2020
-
Abstract
- <bold>Background: </bold>Therapeutic options are limited for advanced, metastatic biliary tract cancer. The pivotal NAPOLI-1 trial demonstrated the superior clinical benefit of nanoliposomal irinotecan (Nal-IRI) in gemcitabine-pretreated patients with metastatic pancreatic ductal adenocarcinoma; however, the antitumor activity of Nal-IRI in biliary tract cancer is unknown. This is the first report describing the efficacy of Nal-IRI in biliary tract cancer.<bold>Methods: </bold>In this multicenter retrospective cohort analysis, we identified patients with metastatic biliary tract adenocarcinoma who were treated with Nal-IRI in combination with 5-fluorouracil and folinic acid following tumor progression under standard therapy at one of the study centers between May 2016 and January 2019. We assessed disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).<bold>Results: </bold>There were 14 patients; the median age at the time of diagnosis and the median age at the initiation of Nal-IRI were 59.3 and 60.0 years, respectively. Nal-IRI in combination with 5-fluorouracil and folinic acid was administered as second-, third-, fourth-, and fifth-line treatment in 6 (43%), 5 (36%), 2 (14%), and 1 (7%) patient with metastatic disease, respectively. The objective DCR with Nal-IRI was 50% (7/14 patients). Six patients (43%) had partial response, and one patient (7%) had stable disease. Progressive disease was observed in seven patients. The median PFS and median OS following Nal-IRI initiation were 10.6 and 24.1 months, respectively.<bold>Conclusions: </bold>This retrospective analysis provides the first evidence that Nal-IRI might exhibit a clinical meaningful antitumor activity in metastatic biliary tract cancer. [ABSTRACT FROM AUTHOR]
- Subjects :
- *FOLINIC acid
*GALLBLADDER
*DACARBAZINE
*BILIARY tract
*PROGRESSION-free survival
*CANCER invasiveness
*THERAPEUTIC use of antineoplastic agents
*ADENOCARCINOMA
*DRUG delivery systems
*ARTIFICIAL membranes
*RESEARCH
*RESEARCH methodology
*DEOXYCYTIDINE
*RETROSPECTIVE studies
*ANTINEOPLASTIC agents
*EVALUATION research
*MEDICAL cooperation
*FLUOROURACIL
*TREATMENT effectiveness
*COMPARATIVE studies
*NANOPARTICLES
BILIARY tract cancer
BILE duct tumors
Subjects
Details
- Language :
- English
- ISSN :
- 03445704
- Volume :
- 86
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Cancer Chemotherapy & Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 144404613
- Full Text :
- https://doi.org/10.1007/s00280-020-04094-0